Crinetics Pharmaceuticals, Inc.
CRNX
$29.15
$0.933.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 361.00K | 0.00 | -- | 399.00K | 640.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 361.00K | 0.00 | -- | 399.00K | 640.00K |
| Cost of Revenue | 76.24M | 66.57M | 61.91M | 58.34M | 53.34M |
| Gross Profit | -75.88M | -66.57M | -61.91M | -57.95M | -52.70M |
| SG&A Expenses | 35.53M | 28.18M | 25.89M | 24.84M | 20.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.77M | 94.75M | 87.80M | 83.18M | 74.17M |
| Operating Income | -111.41M | -94.75M | -87.80M | -82.78M | -73.53M |
| Income Before Tax | -96.77M | -80.60M | -76.83M | -74.06M | -66.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.77M | -80.60M | -76.83M | -74.06M | -66.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.77M | -80.60M | -76.83M | -74.06M | -66.93M |
| EBIT | -111.41M | -94.75M | -87.80M | -82.78M | -73.53M |
| EBITDA | -110.48M | -93.96M | -87.03M | -82.03M | -73.06M |
| EPS Basic | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 |
| Normalized Basic EPS | -0.65 | -0.55 | -0.60 | -0.59 | -0.58 |
| EPS Diluted | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 |
| Normalized Diluted EPS | -0.65 | -0.55 | -0.60 | -0.59 | -0.58 |
| Average Basic Shares Outstanding | 93.10M | 91.49M | 80.09M | 79.01M | 72.29M |
| Average Diluted Shares Outstanding | 93.10M | 91.49M | 80.09M | 79.01M | 72.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |